UY28754A1 - Proceso quimico - Google Patents

Proceso quimico

Info

Publication number
UY28754A1
UY28754A1 UY28754A UY28754A UY28754A1 UY 28754 A1 UY28754 A1 UY 28754A1 UY 28754 A UY28754 A UY 28754A UY 28754 A UY28754 A UY 28754A UY 28754 A1 UY28754 A1 UY 28754A1
Authority
UY
Uruguay
Prior art keywords
chemical process
processes
formula
preparing compounds
chemical
Prior art date
Application number
UY28754A
Other languages
English (en)
Inventor
Margaret Anne Butlin
Roger Butlin
Philip John Hogan
Andreas Meudt
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY28754A1 publication Critical patent/UY28754A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

En la presente se describen procesos para preparar compuestos de Fórmula I y IV
UY28754A 2004-02-20 2005-02-17 Proceso quimico UY28754A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0403744.6A GB0403744D0 (en) 2004-02-20 2004-02-20 Chemical process

Publications (1)

Publication Number Publication Date
UY28754A1 true UY28754A1 (es) 2005-09-30

Family

ID=32040047

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28754A UY28754A1 (es) 2004-02-20 2005-02-17 Proceso quimico

Country Status (32)

Country Link
US (2) US7626020B2 (es)
EP (3) EP2135873B1 (es)
JP (2) JP2007523906A (es)
KR (2) KR101196111B1 (es)
CN (1) CN1922193B (es)
AR (1) AR047810A1 (es)
AT (1) ATE535532T1 (es)
AU (1) AU2005214138B2 (es)
BR (1) BRPI0507847A (es)
CA (1) CA2555554A1 (es)
CL (1) CL2011003138A1 (es)
CY (1) CY1112555T1 (es)
DK (1) DK2135873T3 (es)
ES (1) ES2375201T3 (es)
GB (1) GB0403744D0 (es)
HK (1) HK1139689A1 (es)
HR (1) HRP20120031T1 (es)
IL (2) IL177505A (es)
MY (1) MY142268A (es)
NO (1) NO20064012L (es)
PL (1) PL2135873T3 (es)
PT (1) PT2135873E (es)
RS (1) RS52300B (es)
RU (1) RU2386636C2 (es)
SA (1) SA05260017B1 (es)
SG (1) SG153856A1 (es)
SI (1) SI2135873T1 (es)
TW (1) TWI347947B (es)
UA (1) UA83418C2 (es)
UY (1) UY28754A1 (es)
WO (1) WO2005080403A2 (es)
ZA (1) ZA200606579B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP2079734A1 (en) * 2006-10-25 2009-07-22 NeuroSearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
JP5637982B2 (ja) * 2008-04-09 2014-12-10 インフィニティー ファーマシューティカルズ， インコーポレイテッド 脂肪酸アミド加水分解酵素の阻害剤
US8541581B2 (en) 2009-04-07 2013-09-24 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8546564B2 (en) 2009-04-07 2013-10-01 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2011097233A1 (en) 2010-02-03 2011-08-11 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
DK3362462T3 (da) 2015-10-12 2021-10-11 Advanced Cell Diagnostics Inc In situ-detektion af nukleotidvarianter i prøver med højt støjniveau, og sammensætninger og fremgangsmåder relateret dertil

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
TW270116B (es) 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (es) 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5965732A (en) 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
AU3642795A (en) 1994-09-27 1996-04-19 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
GB2295616A (en) 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
GB9704762D0 (en) * 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
AU3011299A (en) 1998-03-23 1999-10-18 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
JP4652569B2 (ja) 1998-04-29 2011-03-16 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Ｎ−（３−エチニルフェニルアミノ）−６，７−ビス（２−メトキシエトキシ）−４−キナゾリンアミンメシレートの無水物及び一水和物
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
US6355678B1 (en) 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
WO2000021509A2 (en) 1998-10-15 2000-04-20 Imperial College Innovations Limited Methods of treatment
DE19857765A1 (de) * 1998-12-15 2000-06-21 Clariant Gmbh Verfahren zur Herstellung von para-Oxadiazolyl-phenyl-boronsäuren
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
CA2395088A1 (en) 1999-12-15 2001-06-21 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
ES2277856T3 (es) 2000-02-16 2007-08-01 Astellas Pharma Inc. Remedios para enfermedades inducidas por endotelina.
BR0111207A (pt) 2000-05-31 2003-04-01 Warner Lambert Co Combinações de um antagonista receptor de endotelina e um composto antiepiléptico tendo propriedades de alìvio da dor ou analgésicos
US20020055457A1 (en) 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
DE10113366A1 (de) 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2002049630A2 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
KR20040052489A (ko) 2001-03-06 2004-06-23 셀러지 파마세우티칼스, 인크 비뇨생식기 장애 치료용 화합물 및 그 방법
GB0108689D0 (en) 2001-04-05 2001-05-30 Medical Res Council Neuropathologies associated with expression of TNF-a
US20030092757A1 (en) 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
AR033465A1 (es) 2001-04-11 2003-12-17 Abbott Lab El uso de un antagonista del receptor de endotelina en la fabricacion de un medicamento util en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata
WO2003006041A1 (fr) 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Agents prophylactiques/therapeutiques contre les tumeurs malignes
WO2003009805A2 (en) 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
EP1411933A1 (en) * 2001-08-03 2004-04-28 SmithKline Beecham Corporation Alpha-ketoamide derivatives as cathepsin k inhibitors
US20050215528A1 (en) 2001-08-10 2005-09-29 Shuichi Furuya Gnrh agonist combination drugs
DE10155076A1 (de) 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223367D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
SI1761515T1 (sl) 2003-12-20 2009-02-28 Merck Patent Gmbh 2-(hetero-)aril substituirani derivati tetrahidrokinolina
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) 2005-07-19 2005-08-24 Astrazeneca Ab Salt

Also Published As

Publication number Publication date
AR047810A1 (es) 2006-02-22
SG153856A1 (en) 2009-07-29
KR20120036998A (ko) 2012-04-18
EP2135873A2 (en) 2009-12-23
ES2375201T3 (es) 2012-02-27
SA05260017B1 (ar) 2008-07-14
WO2005080403A3 (en) 2005-11-24
JP2012031174A (ja) 2012-02-16
KR101196111B1 (ko) 2012-10-30
RS52300B (en) 2012-12-31
PT2135873E (pt) 2012-01-16
KR20060129483A (ko) 2006-12-15
UA83418C2 (uk) 2008-07-10
CY1112555T1 (el) 2016-02-10
DK2135873T3 (da) 2012-02-13
RU2006133455A (ru) 2008-03-27
CA2555554A1 (en) 2005-09-01
TW200538451A (en) 2005-12-01
AU2005214138A1 (en) 2005-09-01
US20080161565A1 (en) 2008-07-03
PL2135873T3 (pl) 2012-03-30
CL2011003138A1 (es) 2012-06-22
EP2325189A2 (en) 2011-05-25
SI2135873T1 (sl) 2012-03-30
EP2135873B1 (en) 2011-11-30
IL177505A (en) 2010-12-30
MY142268A (en) 2010-11-15
TWI347947B (en) 2011-09-01
EP1718655A2 (en) 2006-11-08
HK1139689A1 (en) 2010-09-24
HRP20120031T1 (hr) 2012-02-29
RU2386636C2 (ru) 2010-04-20
AU2005214138B2 (en) 2009-02-12
US7626020B2 (en) 2009-12-01
EP2135873A3 (en) 2010-03-24
BRPI0507847A (pt) 2007-07-10
ZA200606579B (en) 2008-01-30
WO2005080403A2 (en) 2005-09-01
GB0403744D0 (en) 2004-03-24
NO20064012L (no) 2006-11-06
CN1922193B (zh) 2012-12-26
IL177505A0 (en) 2006-12-10
IL194709A (en) 2010-12-30
CN1922193A (zh) 2007-02-28
US20100094010A1 (en) 2010-04-15
EP2325189A3 (en) 2011-10-26
JP2007523906A (ja) 2007-08-23
ATE535532T1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
UY28754A1 (es) Proceso quimico
UY29612A1 (es) Compuestos quimicos ii
UY33981A (es) ?método para preparar compuestos macrocíclicos inhibidores de serina proteasas de hepatitis c?.
GB0508318D0 (en) Organic compounds
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
TW200732341A (en) Chemical compounds
CR11492A (es) Peptidil nitrilos y uso de los mismos como inhibidores de dipeptidil peptidasa i
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
GB0508314D0 (en) Organic compounds
ECSP099480A (es) Compuestos químicos 637: piridopirimidindionas como inhibidores de la pde4
TW200716543A (en) Chemical compounds VII
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
MX2011005934A (es) Compuestos organicos.
EA200701707A1 (ru) Пиразолопиримидины
EA200970605A1 (ru) Ингибиторы mapk/erk-киназ
TW200638930A (en) Acetylene derivatives
SE0401762D0 (sv) Novel compounds
CR11824A (es) Derivados heterocíclicos de la urea y sus métodos de empleo
PA8804601A1 (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su producción y su uso como agentes antiinflamatorios.
ECSP099070A (es) Bencilaminas, un proceso para su producción y su uso como agentes anti-inflamatorios
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
TN2009000536A1 (en) Novel herbicides
NO20070550L (no) Fremgangsmate for fremstilling av pyrrolotriazinforbindelser
SE0403085D0 (sv) Novel componds

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160428